Siemens Healthineers to Significantly Expand Its Walpole, Mass. Laboratory Diagnostic Manufacturing Facility

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Siemens Healthineers will invest around $300 million in its Walpole,
Mass. laboratory diagnostics manufacturing and research and development
facility. The investment extends over four years and is another proof
point that Siemens Healthineers invests in innovation to enable
healthcare providers around the world to meet their current challenges
and to excel in their respective environments. Through products and
solutions designed to increase efficiency and reduce costs, Siemens
Healthineers sets new trends in healthcare together with its customers –
working under the motto “Engineering Success. Pioneering Healthcare.
Together.”

“The expansion of the Walpole facility fits into the strategic growth
plans for the company and allows us to increase our manufacturing
footprint in the United States, the largest healthcare market in the
world,” said Bernd Montag, Chief Executive Officer, Siemens
Healthineers.“The laboratory instruments and reagents developed and
manufactured at the Siemens Healthineers Walpole facility impact
patients and healthcare providers across the globe.”

The Walpole facility currently employs more than 700 employees and is
the main manufacturing facility for assays that run on the ADVIA®
Centaur family of immunoassay instruments, and for consumables for the
company’s molecular and blood gas testing instruments. The facility will
also manufacture assays to run on the immunoassay module of the
Atellica™ Solution¹, which is currently under FDA review. R&D efforts at
the site bring new tests to the diagnostics market to help physicians
diagnose and treat disease.

“With a 37-year history of manufacturing products in Walpole, we saw an
opportunity to leverage the local talent in the community to further our
growth and expansion plans,” said Franz Walt, President, Laboratory
Diagnostics, Siemens Healthineers.

The company plans to upgrade and expand its existing 500,000 sq. ft.
complex. Renovations to the existing facility will begin in the coming
weeks. The expansion—which will include manufacturing, warehouse, office
and lab space—is set to begin in the summer. Siemens Healthineers is
committed to creating at least 400 positions. The company anticipates
that it may ultimately create up to as many as 700 new permanent jobs to
bring the total employment at the site to between 1,300 and 1,600 by
2026. These employees will join the 46,000 Siemens Healthineers around
the world who enable healthcare providers to deliver excellent patient
care.

“I am proud that Siemens has chosen to grow its laboratory diagnostics
unit in Massachusetts,” said Governor Charlie Baker. “The Commonwealth
is pleased to continue building a pro-growth economic environment that
creates more jobs for our communities, and remains focused on supporting
globally competitive life sciences and advanced manufacturing. I thank
Siemens Healthineers for their commitment to Massachusetts, and look
forward to continuing to partner with the company to move this important
economic development project forward.”

¹ Product is under FDA review. Not available for sale. Future
availability cannot be guaranteed.
² Based on data presented by RKG
Associates Economic Impact Analysis

Siemens Healthineers is the separately managed healthcare
business of Siemens AG enabling healthcare providers worldwide to meet
their current challenges and to excel in their respective environments.
A leader in medical technology, Siemens Healthineers is constantly
innovating its portfolio of products and services in its core areas of
diagnostic and therapeutic imaging and in laboratory diagnostics and
molecular medicine. Siemens Healthineers is also actively developing its
digital health services and enterprise services. To help customers
succeed in today’s dynamic healthcare marketplace, Siemens Healthineers
is championing new business models that maximize opportunity and
minimize risk for healthcare providers. In fiscal 2016, which ended on
September 30, 2016, Siemens Healthineers generated revenue of €13.5
billion and profit of over €2.3 billion and has about 46,000 employees
worldwide. Further information is available at www.siemens.com/healthineers.

This document contains statements related to our future business and
financial performance and future events or developments involving
Siemens that may constitute forward-looking statements. These statements
may be identified by words such as « expect, » « look forward to, »
« anticipate » « intend, » « plan, » « believe, » « seek, » « estimate, » « will, »
« project » or words of similar meaning. We may also make forward-looking
statements in other reports, in presentations, in material delivered to
shareholders and in press releases. In addition, our representatives may
from time to time make oral forward-looking statements. Such statements
are based on the current expectations and certain assumptions of
Siemens’ management, of which many are beyond Siemens’ control. These
are subject to a number of risks, uncertainties and factors, including,
but not limited to those described in disclosures, in particular in the
chapter Risks in the Annual Report. Should one or more of these risks or
uncertainties materialize, or should underlying expectations not occur
or assumptions prove incorrect, actual results, performance or
achievements of Siemens may (negatively or positively) vary materially
from those described explicitly or implicitly in the relevant
forward-looking statement. Siemens neither intends, nor assumes any
obligation, to update or revise these forward-looking statements in
light of developments which differ from those anticipated.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161214005191/en/